Geron Corp. has published a third approach for making use of its telomerase technology to prevent cancer, reporting that immunization of antigen presenting dendritic cells against the catalytic subunit of telomerase can induce immunity against tumors that express telomerase.

Telomerase is an attractive target because 85 percent of human tumors have elevated levels of telomerase, including the most common cancers. GERN's three approaches include small molecule telomerase inhibitors, oncolytic viruses, and now a telomerase vaccine.